CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: L2HGDH (ImmuneEditome ID:79944)

1. Gene summary of enriched editing regions for L2HGDH

check button Gene summary
Gene informationGene symbol

L2HGDH

Gene ID

79944

GeneSynonymsC14orf160|L2HGA
GeneCytomap

14q21.3

GeneTypeprotein-coding
GeneDescriptionL-2-hydroxyglutarate dehydrogenase, mitochondrial|2-hydroxyglutarate dehydrogenase|L-alpha-hydroxyglutarate dehydrogenase|alpha-hydroxyglutarate oxidoreductase|alpha-ketoglutarate reductase|duranin
GeneModificationdate20230329
UniprotIDQ9H9P8;G3V5S1;C9JVN9;G3V272;G3V3E2
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr14:50245830-50246910:-ENST00000267436.7ENSG00000087299.10L2HGDHUTR3AluSq2,AluJb,(ATT)n,AluJo,AluSxchr14:50245830-50246910:-.alignment
chr14:50245830-50246910:-ENST00000421284.6ENSG00000087299.10L2HGDHUTR3AluSq2,AluJb,(ATT)n,AluJo,AluSxchr14:50245830-50246910:-.alignment
chr14:50287745-50289541:-ENST00000261699.7ENSG00000087299.10L2HGDHintronicLTR54,L1MC1,AluSp,AluSx1,L1MA5,A-richchr14:50287745-50289541:-.alignment
chr14:50287745-50289541:-ENST00000267436.7ENSG00000087299.10L2HGDHintronicLTR54,L1MC1,AluSp,AluSx1,L1MA5,A-richchr14:50287745-50289541:-.alignment
chr14:50287745-50289541:-ENST00000421284.6ENSG00000087299.10L2HGDHintronicLTR54,L1MC1,AluSp,AluSx1,L1MA5,A-richchr14:50287745-50289541:-.alignment
chr14:50287745-50289541:-ENST00000555423.4ENSG00000087299.10L2HGDHintronicLTR54,L1MC1,AluSp,AluSx1,L1MA5,A-richchr14:50287745-50289541:-.alignment
chr14:50287745-50289541:-ENST00000555610.1ENSG00000087299.10L2HGDHintronicLTR54,L1MC1,AluSp,AluSx1,L1MA5,A-richchr14:50287745-50289541:-.alignment
chr14:50295460-50295899:-ENST00000261699.7ENSG00000087299.10L2HGDHintronicAluSq2,(T)n,AluJbchr14:50295460-50295899:-.alignment
chr14:50295460-50295899:-ENST00000267436.7ENSG00000087299.10L2HGDHintronicAluSq2,(T)n,AluJbchr14:50295460-50295899:-.alignment
chr14:50295460-50295899:-ENST00000421284.6ENSG00000087299.10L2HGDHintronicAluSq2,(T)n,AluJbchr14:50295460-50295899:-.alignment
chr14:50295460-50295899:-ENST00000554191.4ENSG00000087299.10L2HGDHintronicAluSq2,(T)n,AluJbchr14:50295460-50295899:-.alignment
chr14:50295460-50295899:-ENST00000555423.4ENSG00000087299.10L2HGDHintronicAluSq2,(T)n,AluJbchr14:50295460-50295899:-.alignment
chr14:50295460-50295899:-ENST00000555610.1ENSG00000087299.10L2HGDHintronicAluSq2,(T)n,AluJbchr14:50295460-50295899:-.alignment
chr14:50306680-50306919:-ENST00000556393.1ENSG00000087299.10L2HGDHncRNA_intronicAluSxchr14:50306680-50306919:-.alignment
chr14:50309040-50311195:-ENST00000556393.1ENSG00000087299.10L2HGDHncRNA_intronicAluSx1,L2,L1MD,AluJb,AluJr,AluSx,FLAM_C,L1MD2chr14:50309040-50311195:-.alignment


Top

2. Tumor-specific enriched editing regions for L2HGDH


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr14:50245830-50246910:-HNSCEER2.4453e-03image
ENSG00000087299.10,L2HGDHHNSCEAG1.6795e-03image
chr14:50245830-50246910:-KIRCEER1.1888e-05image
ENSG00000087299.10,L2HGDHKIRCEAG2.2584e-06image
chr14:50245830-50246910:-KIRPEER3.4945e-02image
ENSG00000087299.10,L2HGDHKIRPEAG2.9141e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr14:50245830-50246910:-READEER4.9055e-032.6299e-021.3614e+12image
ENSG00000087299.10,L2HGDHREADEAG4.9055e-032.6299e-021.3614e+12image

Top

3. Enriched editing regions and immune related genes for L2HGDH


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr14:50245830-50246910:-KICHEERENSG00000116903,EXOC8-0.57644.2150e-022.4258e-04-0.4717imageNBUD13;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;EIF4A3;ELAVL1;FBL;FMR1;FXR1;HNRNPC;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LIN28;LIN28B;PRPF8;RBM10;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;ZNF184EXOC8Macrophages_M0GSVA_HALLMARK_PROTEIN_SECRETION
chr14:50245830-50246910:-KICHEERENSG00000132305,IMMT-0.56734.3188e-021.8714e-04-0.4791imageNACIN1;BUD13;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;EIF4A3;ELAVL1;FBL;FMR1;FXR1;HNRNPA2B1;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LIN28;LIN28B;PCBP2;PRPF8;RBM10;RBM22;SF3A3;SF3B4;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;ZNF184NAMacrophages_M0GSVA_HALLMARK_ADIPOGENESIS
chr14:50245830-50246910:-KICHEERENSG00000116903,EXOC8-0.57644.2150e-022.4258e-04-0.4717imageNBUD13;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;EIF4A3;ELAVL1;FBL;FMR1;FXR1;HNRNPC;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LIN28;LIN28B;PRPF8;RBM10;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;ZNF184EXOC8Macrophages_M0GSVA_HALLMARK_PROTEIN_SECRETION
chr14:50245830-50246910:-KICHEERENSG00000132305,IMMT-0.56734.3188e-021.8714e-04-0.4791imageNACIN1;BUD13;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;EIF4A3;ELAVL1;FBL;FMR1;FXR1;HNRNPA2B1;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LIN28;LIN28B;PCBP2;PRPF8;RBM10;RBM22;SF3A3;SF3B4;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;ZNF184NAMacrophages_M0GSVA_HALLMARK_ADIPOGENESIS

More results



Top

4. Enriched editing regions and immune related splicing for L2HGDH


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for L2HGDH


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr14:50245830-50246910:-BRCAEERT_cells_regulatory_(Tregs)1.0684e-02-0.0933image
ENSG00000087299.10,L2HGDHBRCAEAGT_cells_regulatory_(Tregs)1.8178e-03-0.1132image
chr14:50245830-50246910:-CESCEERB_cells_memory2.2374e-020.1631image
ENSG00000087299.10,L2HGDHCESCEAGB_cells_memory2.5798e-030.2120image
chr14:50245830-50246910:-COADEERNeutrophils3.3656e-020.1571image
ENSG00000087299.10,L2HGDHCOADEAGNeutrophils6.0495e-030.1985image
chr14:50245830-50246910:-ESCAEERMacrophages_M23.3961e-050.3254image
chr14:50309040-50311195:-ESCAEERMacrophages_M01.4353e-02-0.3285image
ENSG00000087299.10,L2HGDHESCAEAGMacrophages_M22.1818e-030.2428image
chr14:50245830-50246910:-GBMEEREosinophils5.6948e-030.2746image
ENSG00000087299.10,L2HGDHGBMEAGEosinophils1.8423e-020.2342image
chr14:50245830-50246910:-KICHEERT_cells_CD4_memory_activated1.1152e-030.4244image
ENSG00000087299.10,L2HGDHKICHEAGT_cells_CD4_memory_activated1.1152e-030.4244image
chr14:50245830-50246910:-KIRCEERMacrophages_M21.4716e-03-0.2132image
ENSG00000087299.10,L2HGDHKIRCEAGMacrophages_M21.2864e-03-0.2138image
chr14:50245830-50246910:-KIRPEERT_cells_CD4_memory_resting4.3503e-020.1555image
ENSG00000087299.10,L2HGDHKIRPEAGT_cells_CD4_memory_resting2.6596e-020.1696image
chr14:50245830-50246910:-LGGEERT_cells_CD4_naive3.5473e-020.1151image
ENSG00000087299.10,L2HGDHLGGEAGT_cells_CD4_naive3.6673e-020.1144image
chr14:50245830-50246910:-LIHCEEREosinophils4.9585e-030.2184image
ENSG00000087299.10,L2HGDHLIHCEAGEosinophils4.7929e-030.2186image
chr14:50245830-50246910:-LUSCEERNK_cells_activated9.8278e-03-0.1453image
ENSG00000087299.10,L2HGDHLUSCEAGNK_cells_activated9.4147e-03-0.1461image
chr14:50309040-50311195:-OVEERDendritic_cells_activated3.8625e-030.3976image
ENSG00000087299.10,L2HGDHPAADEAGMast_cells_activated1.3814e-030.4577image
chr14:50245830-50246910:-PCPGEERT_cells_gamma_delta3.2562e-050.5832image
ENSG00000087299.10,L2HGDHPCPGEAGT_cells_gamma_delta3.2562e-050.5832image
chr14:50245830-50246910:-PRADEERT_cells_CD84.1996e-02-0.1295image
ENSG00000087299.10,L2HGDHPRADEAGDendritic_cells_activated1.4762e-020.1514image
chr14:50245830-50246910:-SARCEERDendritic_cells_activated9.6698e-030.3236image
ENSG00000087299.10,L2HGDHSARCEAGDendritic_cells_activated1.6799e-020.2957image
chr14:50245830-50246910:-SKCMEERT_cells_follicular_helper2.8459e-020.1542image
ENSG00000087299.10,L2HGDHSKCMEAGT_cells_follicular_helper2.7709e-020.1545image
chr14:50245830-50246910:-STADEERNK_cells_resting3.0481e-020.1225image
chr14:50287745-50289541:-STADEERT_cells_regulatory_(Tregs)2.8779e-020.4559image
chr14:50295460-50295899:-STADEERNeutrophils2.8424e-020.2392image
chr14:50306680-50306919:-STADEERMacrophages_M17.9202e-03-0.4478image
chr14:50309040-50311195:-STADEERMonocytes3.2172e-030.3008image
ENSG00000087299.10,L2HGDHSTADEAGMonocytes1.6697e-020.1350image
chr14:50245830-50246910:-TGCTEERT_cells_regulatory_(Tregs)4.1709e-02-0.2407image
chr14:50245830-50246910:-THCAEERDendritic_cells_activated4.1875e-020.1331image
ENSG00000087299.10,L2HGDHTHCAEAGDendritic_cells_activated2.9494e-020.1420image
chr14:50245830-50246910:-THYMEERMast_cells_activated3.7302e-02-0.4683image
chr14:50245830-50246910:-UCSEERNK_cells_activated2.5483e-02-0.4860image
ENSG00000087299.10,L2HGDHUCSEAGT_cells_follicular_helper2.7124e-02-0.4814image


Top

6. Enriched editing regions and immune gene sets for L2HGDH


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000087299.10,L2HGDHBLCAGSVA_HALLMARK_DNA_REPAIREAG3.9924e-05-0.2941image
chr14:50245830-50246910:-BLCAGSVA_HALLMARK_DNA_REPAIREER8.4893e-05-0.2841image
ENSG00000087299.10,L2HGDHBRCAGSVA_HALLMARK_DNA_REPAIREAG1.1600e-02-0.0918image
chr14:50245830-50246910:-BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEER9.6439e-030.0946image
ENSG00000087299.10,L2HGDHCESCGSVA_HALLMARK_UV_RESPONSE_DNEAG5.3126e-04-0.2428image
chr14:50245830-50246910:-CESCGSVA_HALLMARK_UV_RESPONSE_DNEER1.7884e-03-0.2217image
ENSG00000087299.10,L2HGDHCOADGSVA_HALLMARK_MYC_TARGETS_V2EAG1.3259e-04-0.2737image
chr14:50245830-50246910:-COADGSVA_HALLMARK_ANGIOGENESISEER4.0016e-020.1520image
ENSG00000087299.10,L2HGDHESCAGSVA_HALLMARK_ANGIOGENESISEAG2.1944e-020.1828image
chr14:50245830-50246910:-ESCAGSVA_HALLMARK_COAGULATIONEER1.2025e-030.2570image
chr14:50309040-50311195:-ESCAGSVA_HALLMARK_UV_RESPONSE_UPEER1.0952e-02-0.3406image
ENSG00000087299.10,L2HGDHGBMGSVA_HALLMARK_E2F_TARGETSEAG1.9586e-02-0.2320image
chr14:50245830-50246910:-GBMGSVA_HALLMARK_E2F_TARGETSEER1.9542e-02-0.2332image
ENSG00000087299.10,L2HGDHHNSCGSVA_HALLMARK_HEME_METABOLISMEAG1.1719e-02-0.1483image
chr14:50245830-50246910:-HNSCGSVA_HALLMARK_BILE_ACID_METABOLISMEER4.8123e-02-0.1172image
chr14:50245830-50246910:-KICHGSVA_HALLMARK_HEME_METABOLISMEER4.7443e-06-0.5690image
ENSG00000087299.10,L2HGDHKICHGSVA_HALLMARK_HEME_METABOLISMEAG4.7443e-06-0.5690image
chr14:50245830-50246910:-KIRCGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER1.3102e-030.2154image
ENSG00000087299.10,L2HGDHKIRCGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG6.5361e-030.1812image
ENSG00000087299.10,L2HGDHKIRPGSVA_HALLMARK_ANDROGEN_RESPONSEEAG4.9796e-02-0.1503image
chr14:50245830-50246910:-LGGGSVA_HALLMARK_G2M_CHECKPOINTEER1.8087e-04-0.2035image
ENSG00000087299.10,L2HGDHLGGGSVA_HALLMARK_G2M_CHECKPOINTEAG2.1224e-04-0.2014image
ENSG00000087299.10,L2HGDHLIHCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.4771e-02-0.1895image
chr14:50245830-50246910:-LIHCGSVA_HALLMARK_UV_RESPONSE_DNEER1.3773e-020.1920image
ENSG00000087299.10,L2HGDHLUADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG1.7006e-020.1511image
chr14:50245830-50246910:-LUADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER9.4972e-030.1647image
chr14:50245830-50246910:-LUSCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER4.1793e-030.1610image
ENSG00000087299.10,L2HGDHLUSCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG4.0015e-030.1617image
chr14:50309040-50311195:-OVGSVA_HALLMARK_MYC_TARGETS_V2EER8.5936e-040.4524image
ENSG00000087299.10,L2HGDHOVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.3415e-020.1520image
chr14:50245830-50246910:-OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER5.8617e-030.1695image
chr14:50245830-50246910:-PCPGGSVA_HALLMARK_DNA_REPAIREER3.2849e-02-0.3223image
ENSG00000087299.10,L2HGDHPCPGGSVA_HALLMARK_DNA_REPAIREAG3.2849e-02-0.3223image
chr14:50245830-50246910:-PRADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.5084e-03-0.1851image
ENSG00000087299.10,L2HGDHPRADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG4.6874e-05-0.2501image
chr14:50245830-50246910:-READGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.3539e-020.3541image
chr14:50245830-50246910:-SARCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER2.1026e-02-0.2902image
ENSG00000087299.10,L2HGDHSARCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.9811e-02-0.2884image
chr14:50295460-50295899:-STADGSVA_HALLMARK_HYPOXIAEER9.9550e-030.2798image
chr14:50245830-50246910:-STADGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER1.3559e-030.1806image
chr14:50306680-50306919:-STADGSVA_HALLMARK_HEME_METABOLISMEER2.2234e-040.5925image
chr14:50287745-50289541:-STADGSVA_HALLMARK_G2M_CHECKPOINTEER3.6938e-03-0.5803image
ENSG00000087299.10,L2HGDHSTADGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG2.5425e-030.1698image
chr14:50309040-50311195:-STADGSVA_HALLMARK_APICAL_SURFACEEER4.2277e-050.4092image
ENSG00000087299.10,L2HGDHTGCTGSVA_HALLMARK_DNA_REPAIREAG4.9653e-02-0.2290image
chr14:50245830-50246910:-TGCTGSVA_HALLMARK_MITOTIC_SPINDLEEER6.6240e-030.3172image
chr14:50245830-50246910:-THCAGSVA_HALLMARK_KRAS_SIGNALING_DNEER6.5426e-040.2212image
ENSG00000087299.10,L2HGDHTHCAGSVA_HALLMARK_KRAS_SIGNALING_DNEAG7.0469e-040.2195image
chr14:50245830-50246910:-THYMGSVA_HALLMARK_GLYCOLYSISEER2.3552e-02-0.5037image
ENSG00000087299.10,L2HGDHTHYMGSVA_HALLMARK_GLYCOLYSISEAG2.3875e-02-0.4693image
ENSG00000087299.10,L2HGDHUCECGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG2.5995e-02-0.2260image
chr14:50245830-50246910:-UCECGSVA_HALLMARK_ADIPOGENESISEER1.0979e-02-0.2669image
ENSG00000087299.10,L2HGDHUCSGSVA_HALLMARK_DNA_REPAIREAG7.0000e-03-0.5698image
chr14:50245830-50246910:-UCSGSVA_HALLMARK_DNA_REPAIREER7.1099e-03-0.5690image


Top

7. Enriched editing regions and drugs for L2HGDH


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr14:50245830-50246910:-BLCALapatinibEER9.0723e-04-0.2413image
ENSG00000087299.10,L2HGDHBLCAMethotrexateEAG1.6478e-030.2274image
ENSG00000087299.10,L2HGDHBRCAAZD6482EAG1.7242e-02-0.0867image
chr14:50245830-50246910:-CESCDasatinibEER6.0331e-03-0.1955image
ENSG00000087299.10,L2HGDHCESCBMS.536924EAG3.0099e-02-0.1534image
chr14:50245830-50246910:-COADCI.1040EER1.1137e-03-0.2391image
ENSG00000087299.10,L2HGDHCOADCCT007093EAG1.1651e-05-0.3121image
ENSG00000087299.10,L2HGDHESCABIBW2992EAG4.5924e-020.1596image
chr14:50309040-50311195:-ESCAAKT.inhibitor.VIIIEER1.1847e-02-0.3371image
chr14:50245830-50246910:-ESCABexaroteneEER2.7232e-03-0.2384image
chr14:50245830-50246910:-GBMA.443654EER1.1616e-020.2514image
ENSG00000087299.10,L2HGDHGBMA.443654EAG1.0712e-020.2529image
ENSG00000087299.10,L2HGDHHNSCCEP.701EAG2.6939e-05-0.2447image
chr14:50245830-50246910:-HNSCCEP.701EER6.3543e-04-0.2012image
ENSG00000087299.10,L2HGDHKICHGSK269962AEAG5.0696e-04-0.4497image
chr14:50245830-50246910:-KICHGSK269962AEER5.0696e-04-0.4497image
ENSG00000087299.10,L2HGDHKIRCGW.441756EAG4.6331e-020.1333image
chr14:50245830-50246910:-LGGImatinibEER7.2697e-05-0.2153image
ENSG00000087299.10,L2HGDHLGGImatinibEAG7.6422e-05-0.2147image
chr14:50245830-50246910:-LIHCBMS.708163EER1.7183e-02-0.1859image
ENSG00000087299.10,L2HGDHLIHCBMS.708163EAG1.8886e-02-0.1826image
ENSG00000087299.10,L2HGDHLUADCI.1040EAG4.1598e-04-0.2220image
chr14:50245830-50246910:-LUADCI.1040EER3.1499e-04-0.2274image
chr14:50245830-50246910:-LUSCBMS.708163EER7.4746e-04-0.1890image
ENSG00000087299.10,L2HGDHLUSCBMS.708163EAG7.1465e-04-0.1897image
chr14:50245830-50246910:-OVAKT.inhibitor.VIIIEER1.5818e-030.1939image
chr14:50309040-50311195:-OVAUY922EER4.9896e-02-0.2761image
ENSG00000087299.10,L2HGDHOVAKT.inhibitor.VIIIEAG8.6532e-040.2038image
ENSG00000087299.10,L2HGDHPAADABT.263EAG2.7805e-030.4356image
ENSG00000087299.10,L2HGDHPCPGLFM.A13EAG1.6832e-02-0.3586image
chr14:50245830-50246910:-PCPGLFM.A13EER1.6832e-02-0.3586image
ENSG00000087299.10,L2HGDHPRADKIN001.135EAG9.6191e-050.2400image
chr14:50245830-50246910:-PRADAZD8055EER1.3229e-030.2032image
ENSG00000087299.10,L2HGDHREADGW.441756EAG1.9816e-030.4312image
chr14:50245830-50246910:-READGW.441756EER5.0091e-030.3986image
ENSG00000087299.10,L2HGDHSARCFTI.277EAG1.7499e-020.2939image
chr14:50245830-50246910:-SARCFTI.277EER2.0173e-020.2921image
chr14:50245830-50246910:-SKCMLapatinibEER1.3345e-020.1738image
ENSG00000087299.10,L2HGDHSKCMLapatinibEAG1.3127e-020.1738image
ENSG00000087299.10,L2HGDHSTADGDC.0449EAG1.8251e-02-0.1332image
chr14:50245830-50246910:-STADGW.441756EER6.4716e-030.1538image
chr14:50287745-50289541:-STADBIRB.0796EER2.5922e-030.5978image
chr14:50309040-50311195:-STADJNJ.26854165EER1.5618e-04-0.3803image
chr14:50245830-50246910:-TGCTAZ628EER3.2153e-030.3426image
ENSG00000087299.10,L2HGDHTGCTAZ628EAG1.2926e-020.2877image
chr14:50245830-50246910:-THCAGSK269962AEER2.1349e-06-0.3041image
ENSG00000087299.10,L2HGDHTHCAGSK269962AEAG1.0633e-05-0.2829image
chr14:50245830-50246910:-THYMA.770041EER1.2514e-020.5472image
ENSG00000087299.10,L2HGDHUCECCMKEAG7.8348e-03-0.2685image
chr14:50245830-50246910:-UCECGSK269962AEER1.2676e-02-0.2618image
ENSG00000087299.10,L2HGDHUCSDocetaxelEAG6.9025e-030.5707image
chr14:50245830-50246910:-UCSLenalidomideEER2.8692e-03-0.6173image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType